Literature DB >> 11689608

Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions.

D A Einfeld1, R Schroeder, P W Roelvink, A Lizonova, C R King, I Kovesdi, T J Wickham.   

Abstract

The development of tissue-selective virus-based vectors requires a better understanding of the role of receptors in gene transfer in vivo, both to rid the vectors of their native tropism and to introduce new specificity. CAR and alphav integrins have been identified as the primary cell surface components that interact with adenovirus type 5 (Ad5)-based vectors during in vitro transduction. We have constructed a set of four vectors, which individually retain the wild-type cell interactions, lack CAR binding, lack alphav integrin binding, or lack both CAR and alphav integrin binding. These vectors have been used to examine the roles of CAR and alphav integrin in determining the tropism of Ad vectors in a mouse model following intrajugular or intramuscular injection. CAR was found to play a significant role in liver transduction. The absence of CAR binding alone, however, had little effect on the low level of expression from Ad in other tissues. Binding of alphav integrins appeared to have more influence than did binding of CAR in promoting the expression in these tissues and was also found to be important in liver transduction by Ad vectors. An effect of the penton base modification was a reduction in the number of vector genomes that could be detected in several tissues. In the liver, where CAR binding is important, combining defects in CAR and alphav integrin binding was essential to effectively reduce the high level of expression from Ad vectors. While there may be differences in Ad vector tropism among species, our results indicate that both CAR and alphav integrins can impact vector distribution in vivo. Disruption of both CAR and alphav integrin interactions may be critical for effectively reducing native tropism and enhancing the efficacy of specific targeting ligands in redirecting Ad vectors to target tissues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689608      PMCID: PMC114713          DOI: 10.1128/JVI.75.23.11284-11291.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.

Authors:  A Lieber; C Y He; L Meuse; D Schowalter; I Kirillova; B Winther; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5).

Authors:  K R Zinn; J T Douglas; C A Smyth; H G Liu; Q Wu; V N Krasnykh; J D Mountz; D T Curiel; J M Mountz
Journal:  Gene Ther       Date:  1998-06       Impact factor: 5.250

3.  Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia.

Authors:  R W Walters; T Grunst; J M Bergelson; R W Finberg; M J Welsh; J Zabner
Journal:  J Biol Chem       Date:  1999-04-09       Impact factor: 5.157

4.  Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice.

Authors:  D L Gu; A M Gonzalez; M A Printz; J Doukas; W Ying; M D'Andrea; D K Hoganson; D T Curiel; J T Douglas; B A Sosnowski; A Baird; S L Aukerman; G F Pierce
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

Review 5.  Vascular targeting with phage peptide libraries.

Authors:  R Pasqualini
Journal:  Q J Nucl Med       Date:  1999-06

6.  The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F.

Authors:  P W Roelvink; A Lizonova; J G Lee; Y Li; J M Bergelson; R W Finberg; D E Brough; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses.

Authors:  J M Bergelson; A Krithivas; L Celi; G Droguett; M S Horwitz; T Wickham; R L Crowell; R W Finberg
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures.

Authors:  S Hemmi; R Geertsen; A Mezzacasa; I Peter; R Dummer
Journal:  Hum Gene Ther       Date:  1998-11-01       Impact factor: 5.695

9.  Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer.

Authors:  R J Pickles; D McCarty; H Matsui; P J Hart; S H Randell; R C Boucher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Adenoviral-mediated gene transfer in lymphocytes.

Authors:  R P Leon; T Hedlund; S J Meech; S Li; J Schaack; S P Hunger; R C Duke; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

View more
  56 in total

1.  Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types.

Authors:  Clare E Thomas; Penny Edwards; Thomas J Wickham; Maria G Castro; Pedro R Lowenstein
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 2.  Targeting gene therapy vectors to the vascular endothelium.

Authors:  Lorraine M Work; Stuart A Nicklin; Andrew H Baker
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

3.  Metabolic biotinylation of recombinant proteins in mammalian cells and in mice.

Authors:  M B Parrott; M A Barry
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

4.  Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.

Authors:  Naoya Koizumi; Hiroyuki Mizuguchi; Fuminori Sakurai; Teruhide Yamaguchi; Yoshiteru Watanabe; Takao Hayakawa
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

5.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Flexibility of the adenovirus fiber is required for efficient receptor interaction.

Authors:  Eugene Wu; Lars Pache; Dan J Von Seggern; Tina-Marie Mullen; Yeshi Mikyas; Phoebe L Stewart; Glen R Nemerow
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

7.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

8.  Reduced infectivity of adenovirus type 5 particles and degradation of entering viral genomes associated with incomplete processing of the preterminal protein.

Authors:  Sayuri E Kato; Jasdave S Chahal; S J Flint
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

9.  Transcriptional control of viral gene therapy by cisplatin.

Authors:  James O Park; Carlos A Lopez; Vinay K Gupta; Charles K Brown; Helena J Mauceri; Thomas E Darga; Abdullah Manan; Samuel Hellman; Mitchell C Posner; Donald W Kufe; Ralph R Weichselbaum
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

10.  Combined transductional untargeting/retargeting and transcriptional restriction enhances adenovirus gene targeting and therapy for hepatic colorectal cancer tumors.

Authors:  Hua-Jung Li; Maaike Everts; Masato Yamamoto; David T Curiel; Harvey R Herschman
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.